Cargando…

Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW Study

PURPOSE: Liver metastasis (LM) is reported in approximately 40% of patients with advanced/metastatic gastric/gastroesophageal junction adenocarcinoma (metastatic esophagogastric adenocarcinoma; mGEA) and is associated with a worse prognosis. This post-hoc analysis from the RAINBOW trial reported the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ogata, Takatsugu, Narita, Yukiya, Wainberg, Zev A., Van Cutsem, Eric, Yamaguchi, Kensei, Piao, Yongzhe, Zhao, Yumin, Peterson, Patrick M., Wijayawardana, Sameera R., Abada, Paolo, Chatterjee, Anindya, Muro, Kei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Gastric Cancer Association 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154140/ https://www.ncbi.nlm.nih.gov/pubmed/37129153 http://dx.doi.org/10.5230/jgc.2023.23.e15

Ejemplares similares

Marked improvement of oral intake with nivolumab monotherapy in a patient with microsatellite instability‐high gastric cancer with insufficient oral intake
por: Ogata, Takatsugu, et al.
Publicado: (2020)

Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial
por: Yamaguchi, Kensei, et al.
Publicado: (2020)

Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
por: Catenacci, Daniel V., et al.
Publicado: (2021)

Updated Immunotherapy for Gastric Cancer
por: Narita, Yukiya, et al.
Publicado: (2023)

Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
por: Van Cutsem, Eric, et al.
Publicado: (2021)

Dramatic Response in a Patient with Metastatic Gastric Cancer Using Trifluridine/Tipiracil after Rapid Disease Progression while on Nivolumab
por: Nozawa, Kazuki, et al.
Publicado: (2020)

Dramatic Response to Trastuzumab Deruxtecan Rechallenge in a Patient with HER2-Positive Gastric Cancer: A Case Report
por: Ogata, Takatsugu, et al.
Publicado: (2022)

Clinical outcomes of patients diagnosed with cancer of unknown primary or malignancy of undefined primary origin who were referred to a regional cancer center
por: Ando, Masashi, et al.
Publicado: (2023)

Decreased liver B vitamin-related enzymes as a metabolic hallmark of cancer cachexia
por: Kojima, Yasushi, et al.
Publicado: (2023)

Early Weight Loss as a Prognostic Factor in Patients with Advanced Gastric Cancer: Analyses from REGARD, RAINBOW, and RAINFALL Phase III Studies
por: Mansoor, Wasat, et al.
Publicado: (2021)

Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma(†)
por: Al-Batran, S.-E., et al.
Publicado: (2016)

Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study
por: Yamaguchi, Kensei, et al.
Publicado: (2021)

Initial Report of Second‐Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi‐Institutional Retrospective Analysis
por: Klempner, Samuel J., et al.
Publicado: (2018)

Exploratory Factor Analysis of Rainbow Trout Serum Chemistry Variables
por: Manera, Maurizio
Publicado: (2021)

First experience of a fully decentralized clinical trial: The dawn of a new era in oncology
por: Taniguchi, Hiroya, et al.
Publicado: (2023)

Real-World Molecular Biomarker Testing Patterns and Results for Advanced Gastroesophageal Cancers in the United States
por: Mehta, Rutika, et al.
Publicado: (2023)

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
por: Bang, Yung-Jue, et al.
Publicado: (2019)

Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer
por: Muro, Kei, et al.
Publicado: (2023)

Is ramucirumab and paclitaxel therapy beneficial for second-line treatment of metastatic gastric or junctional adenocarcinoma for patients with ascites? Analysis of RAINBOW phase 3 trial data
por: Muro, Kei, et al.
Publicado: (2019)

A post-marketing observational study of ramucirumab in patients with gastric cancer in Japan
por: Chen, Yucherng, et al.
Publicado: (2021)

Successful Treatment of Cardiac Angiosarcoma Associated with Disseminated Intravascular Coagulation with Nab-Paclitaxel: A Case Report and Review of the Literature
por: Honda, Kazunori, et al.
Publicado: (2017)

A prospective survey of comprehensive score for financial toxicity in Japanese cancer patients: report on a pilot study
por: Honda, Kazunori, et al.
Publicado: (2018)

RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC
por: Nishio, Makoto, et al.
Publicado: (2022)

The rainbow
por: Lawrence, David Herbert, 1885-1930
Publicado: (1915)

Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study
por: Yoshikawa, Akie Kimura, et al.
Publicado: (2022)

Evaluating clinical impact of a shortened infusion duration for ramucirumab: a model-based approach
por: Gao, Ling, et al.
Publicado: (2021)

Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial
por: Shitara, Kohei, et al.
Publicado: (2023)

Targeted Therapies for Metastatic Esophagogastric Cancer
por: Reddy, Deepa, et al.
Publicado: (2011)

Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma
por: Catenacci, Daniel V.T., et al.
Publicado: (2020)

Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas
por: Klempner, S.J., et al.
Publicado: (2023)

Intra-Examiner and Inter-Examiner Reproducibility of Paraspinal Thermography
por: McCoy, Matthew, et al.
Publicado: (2011)

The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation
por: Mitani, Seiichiro, et al.
Publicado: (2019)

Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data
por: Fuchs, Charles S., et al.
Publicado: (2017)

The Rainbow Sky
por: Buick, Tony
Publicado: (2010)

The Rainbow Dictionary

Gravity's rainbow
por: Pynchon, Thomas

Over the rainbow
por: Saxon, Emma
Publicado: (2015)

The Rainbow Playgroup
Publicado: (1972)

A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer
por: Yamaguchi, Kazuhisa, et al.
Publicado: (2015)

Two Instrument Comparison of Reagents From a US FDA-Approved Assay for the Assessment of Ki-67 in High-Risk Early Breast Cancer
por: Komforti, Miglena, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_soba8u6ir0kujva362si8imnr0